Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib neoadjuvant therapy for resectable stage IIIA EGFR-mutant lung adenocarcinoma
ChiCTR2100053119Phase 2Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Response rate. Started Dec 2021; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053119.